Discordant effects of rosiglitazone on novel inflammatory biomarkers

• Published in: The American heart journal Vol. 165; no. 4; pp. 609 - 614
• Main Authors: Gada, Elan, Owens, Andrew W., Gore, M. Odette, See, Raphael, Abdullah, Shuaib M., Ayers, Colby R., Rohatgi, Anand, Khera, Amit, de Lemos, James A., McGuire, Darren K.
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.04.2013; Elsevier Limited
• Subjects: Aged; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - physiopathology; Biomarkers; Biomarkers - blood; C-Reactive Protein - analysis; C-Reactive Protein - drug effects; Cardiovascular; Cardiovascular disease; Chemokines; Cholesterol; Cytokines - drug effects; Diabetes; Diabetes Mellitus, Type 2 - blood; Female; Glycation End Products, Advanced - drug effects; Heart attacks; Humans; Hypertension; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacology; Ligands; Lymphotoxin beta Receptor - drug effects; Male; Middle Aged; Myocardial Infarction - chemically induced; Pilot Projects; Proteins; Studies; Thiazolidinediones - adverse effects; Thiazolidinediones - pharmacology

Although rosiglitazone favorably affects myriad intermediate markers of atherosclerosis, it appears to increase myocardial infarction (MI) risk. We analyzed the effects of rosiglitazone on a panel of 8 novel circulating biomarkers, 4 of which are independently associated with atherosclerosis: lympho...